Safety of polysorbate 80 in the oncology setting
LS Schwartzberg, RM Navari - Advances in therapy, 2018 - Springer
Polysorbate 80 is a synthetic nonionic surfactant used as an excipient in drug formulation.
Various products formulated with polysorbate 80 are used in the oncology setting for …
Various products formulated with polysorbate 80 are used in the oncology setting for …
Drug induced steatohepatitis: an uncommon culprit of a common disease
L Rabinowich, O Shibolet - BioMed research international, 2015 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in developed
countries. Its frequency is increasing in the general population mostly due to the widespread …
countries. Its frequency is increasing in the general population mostly due to the widespread …
[图书][B] Drug-induced liver disease
N Kaplowitz, LD DeLeve - 2007 - taylorfrancis.com
Featuring more than 4100 references, Drug-Induced Liver Disease is an invaluable
reference for gastroenterologists, hepatologists, family physicians, internists, pathologists …
reference for gastroenterologists, hepatologists, family physicians, internists, pathologists …
Adverse effects of amiodarone
M JAFARI‐FESHARAKI… - Pacing and clinical …, 1998 - Wiley Online Library
Amiodarone was introduced 30 years ago as an antianginal agent and subsequently has
been used as an antiarrhythmic agent. This drug was initially used for patients with …
been used as an antiarrhythmic agent. This drug was initially used for patients with …
Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature
AER Bravo, J Drewe, RG Schlienger… - Critical care …, 2005 - journals.lww.com
Objective: Atrial fibrillation is the most common arrhythmia after cardiac surgery. Amiodarone
can effectively prevent and control postoperative atrial and ventricular fibrillation. Acute …
can effectively prevent and control postoperative atrial and ventricular fibrillation. Acute …
Amiodarone hepatotoxicity
M Babatin, SS Lee, PT Pollak - Current vascular pharmacology, 2008 - ingentaconnect.com
Potential hepatotoxicity related to amiodarone therapy is often a concern when deciding
whether to initiate or continue treatment with this medication. While mostly associated with …
whether to initiate or continue treatment with this medication. While mostly associated with …
[HTML][HTML] Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to< 2 years of age with invasive candidiasis, including candidemia
E Roilides, F Carlesse, M Tawadrous… - The Pediatric …, 2020 - journals.lww.com
Nineteen patients 1 month to< 2 years of age with (n= 16) or at high risk of (n= 3) invasive
candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) …
candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) …
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use
K Raja, SN Thung, MI Fiel… - Seminars in Liver Disease, 2009 - thieme-connect.com
Nonalcoholic steatosis/steatohepatitis is the most common cause for abnormal liver
chemistries. Apart from metabolic syndrome, drugs may also lead to development of …
chemistries. Apart from metabolic syndrome, drugs may also lead to development of …
Acute liver failure with amiodarone infusion: A case report and systematic review
What is known and objective Amiodarone, a commonly used class III antiarrhythmic agent
notable for a relatively long half‐life of up to 6 months and its pronounced adverse effect …
notable for a relatively long half‐life of up to 6 months and its pronounced adverse effect …
Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature
M Nasser, TR Larsen, B Waanbah, I Sidiqi… - Drug, healthcare and …, 2013 - Taylor & Francis
Amiodarone is a benzofuran class III antiarrhythmic drug used to treat a wide spectrum of
ventricular tachyarrhythmias. The parenteral formulation is prepared in polysorbate 80 …
ventricular tachyarrhythmias. The parenteral formulation is prepared in polysorbate 80 …